Gain Therapeutics - Unfolding the next generation of allosteric small molecule therapies to meet patient needs
Lead Program
- Details
- Written by: web web
- Category: Home
- Hits: 3452
Lead Program
Gain’s lead drug candidate is a best-in-class small molecule, for the treatment of GBA-Parkinson’s disease and other neurodegenerative diseases. is currently being evaluated in a Phase I clinical study.
Lead Program >>